Prompt diagnosis key in bladder cancer

Practitioner

Volumn 258, Issue 1767, 2014, Pages 23-27

  DeSouza, Karen ^a   Chowdhury, Simon ^a   Hughes Dr , Simon ^b  

^a Medical Oncology ^*  (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOPSY; BLADDER TUMOR; CYSTOSCOPY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EUROPE; HUMAN; PROGNOSIS; RISK FACTOR; URINALYSIS;

BIOPSY; CYSTOSCOPY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EUROPE; HUMANS; PROGNOSIS; RISK FACTORS; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84893243734     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. www.cancerresearchuk.org/cancerinfo/cancerstats/keyfacts/bladder-cancer
2. Khadra MH, Pickard RS, Charlton M et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163:524-27
3. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA2005; 293:810-16
4. Mariani AJ, Mariani MC, Macchioni C et al. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 1989; 141:350-55
5. Freedman ND, Silverman DT, Hollenbeck AR et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306:737-45
6. Brennan P, Bogillot O, Cordier S et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 casecontrol studies. Int J Cancer2000; 86:289-294
7. Brennan P, Bogillot O, Greiser E et al. The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control2001;12:411-17
8. Samanic C, Kogevinas M, Dosemeci M et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev2006;15:1348-54
9. Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control2000; 7:325-34
10. Cole P, Hoover R, Friedell GH. Occupation and cancer of the lower urinary tract. Cancer 1972; 29:1250-60
11. Hoffman M, Roberts WS, Cavanagh D. Second pelvic malignancies following radiation therapy for cervical cancer. Obstet Gynecol Surv1985; 40:611-17
12. Sella A, Dexeus FH, Chong C et al. Radiation therapyassociated invasive bladder tumors. Urology1989; 33:185-88
13. Kleinerman RA, Boice JD Jr, Storm HH et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer 1995; 76:442-52
14. Boorjian S, Cowan JE, Konety BR et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2007; 177:883-87
15. Travis LB, Curtis RE, Glimelius B et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87:524-30
16. Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477-84
17. Groah SL, Weitzenkamp DA, Lammertse DP et al. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil2002; 83:346-51
18. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184:E675-83.doi:10.1503/cmaj. 112102.Epub 2012 Jul 3
19. Stimson CJ, Cookson MS, Barocas DA et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol 2010;183:1732-37
20. Apolo AB, Riches J, Boyle MG et al. Clinical value of 18F-2-deoxyglucose positron emission tomography (FDG PET) in bladder cancer (abstract). Presented at the 2009 Genitourinary Cancers Symposium
21. Urinary bladder. In: AJCC Cancer Staging Manual, 7th edn. Springer. New York. 2010
22. Ferlay J, Randi G, Bosetti C et al. Declining mortality from bladder cancer in Europe. BJU Int2008, 101:11-9. Epub 2007 Oct 30
23. Babjuk M, Burger M, Zigeuner R et al. Guidelines on non-muscle-invasive bladder cancer (TaTl & CIS). European Association of Urology. 2013
24. Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organisation for Cancer Research and Treatment of Cancer and Medical Research Cancer clinical trials for the prophylactic treatment of stage Ta-T1 bladder cancer. J Urol 1996; 156:1934-41
25. Lerner SP, Au JL. Risk-adapted use of intravesical chemotherapy. BJU Int 2008, 102:1247-53
26. Hussain SA, Stocken DD, Peake DR et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 2004;90: 2106-2111
27. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28:4912-4918
28. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17(10):3173-81
29. Bellmunt J, Orsola A, Wiegel T et al. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 (Suppl 6): vi45-vi49